Valuation: Orion Oyj

Market Cap 9.63B 11.04B 8.88B 8.15B 15.5B 1,064B 15.76B 106B 41.54B 520B 41.44B 40.53B 1,789B P/E 2026 *
17.4x
P/E 2027 * 14.7x
Enterprise Value 9.53B 10.92B 8.79B 8.07B 15.33B 1,053B 15.59B 105B 41.11B 515B 41.01B 40.11B 1,771B EV / Sales 2026 *
4.58x
EV / Sales 2027 * 3.96x
Free-Float
90.5%
Yield 2026 *
2.81%
Yield 2027 * 3.11%
1 day+0.30%
1 week-5.31%
Current month-5.44%
1 month-0.88%
3 months-7.76%
6 months-3.00%
Current year+7.11%
1 week 67
Extreme 67
70.7
1 month 66
Extreme 66
72.6
Current year 62.3
Extreme 62.3
75.1
1 year 56.3
Extreme 56.3
75.1
3 years 32.5
Extreme 32.5
75.1
5 years 32.5
Extreme 32.5
75.1
10 years 24.75
Extreme 24.75
75.1
Manager TitleAgeSince
Chief Executive Officer 59 2022-10-31
Director of Finance/CFO 50 2024-04-30
Chief Operating Officer 46 2021-12-31
Director TitleAgeSince
Director/Board Member 63 2017-03-21
Director/Board Member 65 2017-03-21
Director/Board Member 66 2020-05-05
Change 5-day change 1-year change 3-year change Capi.($)
+0.30%-5.31% - - 10.93B
+0.35%-6.39%+44.70%+157.34% 1,028B
-2.69%-7.57%+57.52%+54.51% 611B
+0.44%-4.14%+27.46%+79.48% 432B
+0.98%-2.74%+28.13%+21.76% 323B
-0.34%-3.79%+26.52%+43.60% 277B
+1.63%-12.52%+17.86%+21.72% 257B
+3.39%+0.95%-25.43%-37.83% 217B
+0.86%-2.66%+20.63%+57.55% 192B
+1.28%-3.42%+17.49%+70.62% 161B
Average +0.94%-5.24%+23.88%+52.08% 388.7B
Weighted average by Cap. +0.69%-5.52%+32.95%+76.70%

Financials

2026 *2027 *
Net sales 2.08B 2.39B 1.92B 1.76B 3.35B 230B 3.41B 22.89B 8.98B 112B 8.96B 8.76B 387B 2.35B 2.7B 2.17B 1.99B 3.79B 260B 3.85B 25.89B 10.16B 127B 10.13B 9.91B 438B
Net income 550M 630M 507M 465M 884M 60.71B 899M 6.04B 2.37B 29.68B 2.37B 2.31B 102B 649M 744M 599M 550M 1.04B 71.72B 1.06B 7.14B 2.8B 35.07B 2.79B 2.73B 121B
Net Debt -100M -115M -92.66M -85.02M -162M -11.09B -164M -1.1B -433M -5.42B -432M -423M -18.66B -312M -357M -288M -264M -501M -34.42B -510M -3.43B -1.34B -16.83B -1.34B -1.31B -57.91B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,132
Date Price Change Volume
26-07-15 €67.80 +0.30% 2,706
26-07-14 €67.60 -1.60% 6,038
26-07-13 €68.70 -0.87% 3,273
26-07-10 €69.30 -1.56% 3,563
26-07-09 €70.40 +0.28% 4,498
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
68.50EUR
Average target price
74.33EUR
Spread / Average Target
+8.52%

Quarterly revenue - Rate of surprise